Health Exec

The gist of the 340B argument is apparent in a side-by-side presentation of recent quotes from a handful of ready, willing and able commentators on the subject.

The great 340B debate: Point vs. counterpoint vs. finger points From the right come heated calls for reform if not outright overhaul of the 340B Drug Pricing Program. From the left, vociferous insistence on letting 340B be, albeit with modest tweaks and fixes. From hospitals and drug manufacturers: finger-pointing.

Two more insurers sue CMS over Medicare Advantage star rating methodology, following victory by Clover Health in June.